Pharmacological Effect of Aminoferrocene in Mice With L1210 Leukemia

Abstract

Aim: To study the cytostatic and some biological effects of aminoferrocene using mice with L1210 lymphoid leukemia. Materials and Methods: Experiments were performed on BDF1 male mice (DBA/2, female × C57Bl/6, male) with transplantable L1210 lymphoid leukemia. Determination of antitumor activity of Benzyl-Fc Boron (Bn), it was injected intraperitoneally 6 times daily, starting on day 2 after L1210 leukemia cell transplantation. Doses of Bn such as 26; 260 and 2600 μg/kg were used. The determination of intracellular content of cardiolipin, thiols, reactive oxygen species (ROS) and also analysis of Annexin V positivity and mitochondrial transmembrane potential (JC-1 staining) were performed with use of flow cytometry. The levels of “free iron” complexes, transferrin active forms and the rate of NO generation were measured by EPR-specroscopy. Results: Six daily injections of Bn at a dose of 26 μg/kg resulted in an increased survival of mice with L1210 leukemia by 28% (p < 0.05). Bn led to an increase of apoptotic cells number and ROS amount in leukemia cells. Besides, Bn caused a decrease of cardiolipin and nonprotein thiol compounds content. The membrane electrochemical potential of cell mitochondria was decreased also after Bn administration. Studies using EPR-spectroscopy revealed a significant increase in a level of “free iron”, content of transferrin active species and generation rate of NO by inducible NO-synthase in L1210 cells after aminoferrocene administration. Conclusion: Our data indicate that Benzyl-Fc Boron can be promising candidate for realizing a new strategy of anticancer therapy with the use of ROS-inducing agents.

Highly Ordered Gold Nanopatterned Indium Tin Oxide Electrodes for Simultaneous Optical and Electrochemical Probing Cell Interactions

“…The differences between cell types become even more evident when the resistance normalized by the projected cell area is plotted as a function of time (Figure d). These findings correlate well with studies comparing the expression levels of biomarkers associated with cancer invasion and metastasis. − Human breast cancer cells of luminal subtype, such as MCF-7 cells, are characterized by increased adhesive properties due to the high level of E-cadherin expression, whereas MCF-10A cells express a lower level of E-cadherin . Furthermore, MCF-10A cells exhibit significant invasive activity in contrast with MCF-7 cells, as evidenced in an invasion assay across a Matrigel barrier .…”

“…42−44 Human breast cancer cells of luminal subtype, such as MCF-7 cells, are characterized by increased adhesive properties due to the high level of E-cadherin expression, 45 whereas MCF-10A cells express a lower level of E-cadherin. 44 Furthermore, MCF-10A cells exhibit significant invasive activity in contrast with MCF-7 cells, as evidenced in an invasion assay across a Matrigel barrier. 42 In other words, the combination of higher mobility and lower density of cell−cell contacts of MCF-10A vs MCF-7 cells results in spaces between cells that are not tight enough to effectively limit current from flowing to the bulk phase.…”

Targeting glypicans through EGFR and JAK/STAT signaling axes drives breast cancer progression

“…1 The expression pattern of the estrogen receptors (ERs) varies among different breast cancer subtypes, affecting the progression of the disease by mediating breast cancer cell properties. [2][3][4] Based solely on ERα expression, breast cancer is divided into two major categories, namely the ERα-positive subtype, characterized by epithelial cell traits and limited metastatic potential, and the ERα-negative subtype, which displays heightened metastatic potential and is correlated with more aggressive phenotypes. 5 The expression of ERβ isoform is correlated with aggressive malignancy and worse survival rates and is significantly expressed in triple-negative breast cancer, suggesting the clinical significance of this isoform.…”

“…16,17 Through interactions with specific ligands such as growth factors, morphogens, and ECM components, GPCs act as coreceptors or modulators of signaling pathways, including Wnt, Hedgehog, and fibroblast growth factor (FGF). [17][18][19] This diverse family of GPCs comprises six members (1)(2)(3)(4)(5)(6) in mammals, each exhibiting distinct tissue distribution and functional properties. 16 By regulating essential cellular processes such as adhesion, migration, proliferation, and differentiation, GPCs significantly contribute to ECM-mediated biological functions and to disease development.…”

“…Breast cancer constitutes a highly heterogeneous disease, which is one of the most prevailing forms of cancer affecting women 1 . The expression pattern of the estrogen receptors (ERs) varies among different breast cancer subtypes, affecting the progression of the disease by mediating breast cancer cell properties 2–4 . Based solely on ERα expression, breast cancer is divided into two major categories, namely the ERα‐positive subtype, characterized by epithelial cell traits and limited metastatic potential, and the ERα‐negative subtype, which displays heightened metastatic potential and is correlated with more aggressive phenotypes 5 .…”